Journals By Industry - Antivirals

GS-7340 is a novel prodrug of tenofovir, the active agent in Viread, or tenofovir disoproxil fumarate. In previous studies, GS-7340 has demonstrated the ability to provide greater antiviral efficacy at a dose that...

RESEARCH TRIANGLE PARK, N.C. -- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that Nancy J. Hutson, Ph.D. was elected to the Company's Board of Directors, effective Friday, January 20, 2012. "We are excited to...

Study also Demonstrated 100% Sustained Virologic Response 12-Weeks Post Treatment with Quadruple Therapy Phase II Investigational Data Published Today in the New England Journal of Medicine PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE:...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/8f5a37/dermatology_therap) has announced the addition of the "Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/e01e5a/influenza_vaccine) has announced the addition of the "Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast" report to their offering. Last few years have seen renewed interest in the...

CAMBRIDGE, Mass. -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2011 financial results on Thursday, February 2, 2012 after the financial markets close. The company will host...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/fea2f0/hepatitis_market_t) has announced the addition of the "Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market"...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/ab5d3f/strategic_analysis) has announced the addition of Frost & Sullivan's new report "Strategic Analysis of Emerging Vaccines Market in India" to their offering. This research service presents an analysis...

FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Royal Merger Sub II Inc. ("Merger Sub II"), for all of the...

NECROBIOSIS LIPOIDICA Aetiology - A rare skin condition in which there is collagen degeneration with granulomatous response, thickened blood vessels and deposition of fat. - Cause unknown but more often occurs in, or...

CHICAGO -- Fitch Ratings believes that Bristol-Myers Squibb Co.'s (Bristol Myers Squibb) purchase of Inhibitex, Inc. (Inhibitex) for approximately $2.5 billion is consistent with the current rating rationale for the company. Fitch rates...

For older adults, the seasonal flu can be very serious, even deadly ST. LOUIS -- The seasonal flu can be serious for everybody. So serious, in fact, that the Centers for Disease Control...

The company has also reported exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684. Based upon these results, the company is planning further exploration of...

This new indication is based on the evaluation of safety, tolerability, pharmacokinetic parameters and efficacy of ISENTRESS through at least 24-weeks, in a multicenter, open-label, non-comparative study, in HIV-1-infected children and adolescents two...

SAN JOSE, Calif. -- Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus...

SAN FRANCISCO -- Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and...

-More than 25,000 people have started treatment for hepatitis C with INCIVEK([R]), positioning Vertex for continued growth, earnings and cashflow in 2012- -Preparations for approval and launch of KALYDECO(TM) ongoing; additional studies of...

* Strategic Acquisition Supports Long-Term Growth Potential of the Company * Builds on Company's Strong Legacy and Commitment in Virology * Enhances Company's Broad HCV Portfolio with Addition of INX-189, a potent NS5B...

FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has received early termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect...